Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.718
/ Totale documenti scaricati: 30.840.525

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Slide background
Certifico 2000/2024: Informazione Utile




/ Documenti disponibili: 43.718 *

/ Totale documenti scaricati: 30.840.525 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile

/ Documenti disponibili: 43.718 *

/ Totale documenti scaricati: 30.840.525 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.718 *

/ Totale documenti scaricati: 30.840.525 *


Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.718 *

/ Totale documenti scaricati: 30.840.525 *

Vedi Abbonamenti Promo 2023

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

/ Documenti disponibili: 43.718 *

/ Totale documenti scaricati: 30.840.525 *


Vedi Abbonamenti Promo 2022

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.


Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2022
Slide background
Certifico 2000/2021: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021








Europe, Rome

FDA revoked the emergency use authorization for chloroquine and hydroxychloroquine

ID 11006 | | Visite: 3685 | News generaliPermalink: https://www.certifico.com/id/11006

FDA revoked the emergency use authorization for chloroquine and hydroxychloroquine

FDA revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate

The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

Today, 15 june 2020, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible.

The agency determined that the legal criteria for issuing an EUA are no longer met. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use. This is the statutory standard for issuance of an EUA.

The Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services originally requested the EUA covering chloroquine and hydroxychloroquine, and the FDA granted the EUA on March 28, 2020 based on the science and data available at the time. Today, in consultation with the FDA, BARDA sent a letter to the FDA requesting revocation of the EUA based on up to date science and data.

“We’ve made clear throughout the public health emergency that our actions will be guided by science and that our decisions may evolve as we learn more about the SARS-CoV-2 virus, review the latest data, and consider the balance of risks versus benefits of treatments for COVID-19,” said FDA Deputy Commissioner for Medical and Scientific Affairs Anand Shah, M.D. “The FDA always underpins its decision-making with the most trustworthy, high-quality, up-to-date evidence available. We will continue to examine all of the emergency use authorizations the FDA has issued and make changes, as appropriate, based on emerging evidence.”

The FDA has a responsibility to regularly review the appropriateness of an EUA, and as such, the agency will review emerging information associated with the emergency uses for the authorized products. Recent results from a large randomized clinical trial in hospitalized patients, a population similar to the population for which chloroquine and hydroxychloroquine were authorized for emergency use, demonstrated that hydroxychloroquine showed no benefit on mortality or in speeding recovery. This outcome was consistent with other new data, including data showing that the suggested dosing regimens for chloroquine and hydroxychloroquine are unlikely to kill or inhibit the virus that causes COVID-19. The totality of scientific evidence currently available indicate a lack of benefit.

“While additional clinical trials continue to evaluate the potential benefit of these drugs in treating or preventing COVID-19, we determined the emergency use authorization was no longer appropriate. This action was taken following a rigorous assessment by scientists in our Center for Drug Evaluation and Research,” said Patrizia Cavazzoni, M.D., acting director of the FDA’s Center for Drug Evaluation. “We remain committed to using every tool at our disposal in collaboration with innovators and researchers to provide sick patients timely access to appropriate new therapies. Our decisions will always be based on objective and rigorous evaluation of the scientific data.This will never change.”

Chloroquine and hydroxychloroquine are both FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved to treat autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. Both drugs have been prescribed for years to help patients with these debilitating, or even deadly, diseases, and FDA has determined that these drugs are safe and effective when used for these diseases in accordance with their FDA-approved labeling. Of note, FDA approved products may be prescribed by physicians for off-label uses if they determine it is appropriate for treating their patients, including during COVID.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

FDA revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. Based on its ongoing analysis of the EUA and emerging scientific data, the FDA determined that chloroquine and hydroxychloroquine are unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. Additionally, in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use.

The agency issued a Press Release and posted FAQs about this action.

Collegati

Tags: News Coronavirus

Ultimi inseriti

Giu 28, 2025 74

Comunicato ANAC del 18 giugno 2025

in News
Comunicato ANAC del 18 giugno 2025 ID 24186 | 28.06.2025 Chiarimenti in merito alla nomina del Responsabile della prevenzione della corruzione e della trasparenza (RPCT) L’Autorità intende rammentare alle amministrazioni e agli enti di provvedere alla nomina del Responsabile della prevenzione della… Leggi tutto
Giu 28, 2025 89

D.g.r. 16 giugno 2025 - n. XII/4563 / Campagne di Citizen Science: rischio di esposizione al gas radon

D.g.r. 16 giugno 2025 - n. XII/4563 / Campagne di Citizen Science: rischio di esposizione al gas radon in ambienti chiusi ID 24185 | 28.06.2025 Regione Lombardia D.g.r. 16 giugno 2025 - n. XII/4563Campagne di Citizen Science, di informazione e di sensibilizzazione per la prevenzione e protezione… Leggi tutto
Decreto Legislativo 30 aprile 2025 n  93
Giu 27, 2025 98

Decreto Legislativo 30 aprile 2025 n. 93

in News
Decreto Legislativo 30 aprile 2025 n. 93 ID 24184 | 27.06.2025 Decreto Legislativo 30 aprile 2025 n. 93 Disposizioni integrative e correttive al decreto legislativo 15 marzo 2024, n. 29, recante disposizioni in materia di politiche in favore delle persone anziane, in attuazione della delega dl cui… Leggi tutto
Giu 27, 2025 110

Raccomandazione ILO n. 3 del 29 ottobre 1919

Raccomandazione ILO n. 3 del 29 ottobre 1919 / Prevenzione rischio dell'antrace (carbonchio) ID 24181 | 27.06.2025 La Conferenza generale dell'Organizzazione internazionale del lavoro, Convocato a Washington dal Governo degli Stati Uniti d'America il 29 ottobre 1919, e Avendo deciso di adottare… Leggi tutto
Giu 27, 2025 72

Convenzione ILO C161 del 26 giugno 1985

Convenzione ILO C161 del 26 giugno 1985 / Servizi di medicina del lavoro ID 24180 | 28.06.2025 / In allegato ILO - Convention concerning Occupational Health Services C161 25 giugno 1985 Geneva, 25 giugno 1985 The General Conference of the International Labour Organisation, Having been convened at… Leggi tutto
ECHA compendium of analytical methods
Giu 27, 2025 123

ECHA compendium of analytical methods for enforcing REACH restrictions - Ed. 3.0 2025

ECHA compendium of analytical methods for enforcing REACH restrictions - Ed. 3.0 2025 ID 24178 | 27.06.2025 / Attached ECHA has updated its compendium of analytical methods to help authorities to enforce and companies to comply with REACH restrictions. The compendium consists of a collection of… Leggi tutto

Ultimi Documenti Abbonati

ECHA compendium of analytical methods
Giu 27, 2025 123

ECHA compendium of analytical methods for enforcing REACH restrictions - Ed. 3.0 2025

ECHA compendium of analytical methods for enforcing REACH restrictions - Ed. 3.0 2025 ID 24178 | 27.06.2025 / Attached ECHA has updated its compendium of analytical methods to help authorities to enforce and companies to comply with REACH restrictions. The compendium consists of a collection of… Leggi tutto
Giu 26, 2025 229

Circolare Ministero dell’Interno n. 19441 del 25/06/2025

Circolare Ministero dell’Interno n. 19441 del 25/06/2025 ID 24173 | 26.06.2025 / In allegato Ministero dell’InternoLegge 25 novembre 2024, n. 177 recante “Interventi in materia di sicurezza stradale e delega al Governo per la revisione del codice della strada, di cui al decreto legislativo 30… Leggi tutto
Impiego e gestione di droni nel SNPA per il monitoraggio e il controllo ambientale
Giu 24, 2025 265

Impiego e gestione di droni nel SNPA per il monitoraggio e il controllo ambientale

Impiego e gestione di droni nel SNPA per il monitoraggio e il controllo ambientale / 2025 ID 24159 | 24.06.2025 / In allegato I velivoli a pilotaggio remoto (più comunemente droni o UAS – Unmanned Aircraft System) e le tecnologie per il telerilevamento ad alta risoluzione costituiscono una tematica… Leggi tutto